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Transformed acute myeloid leukemia in myeloﬁbrosis results in a median survival of less than 5 months. We
identiﬁed 46 of 1048 myeloﬁbrosis patients in the European Group for Blood and Marrow Transplantation
registry who received allogeneic stem cell transplantation for acute leukemia evolving from myeloﬁbrosis.
The cumulative incidence of treatment-related mortality at 1 year was 28% (95% conﬁdence interval, 14 to 42)
and of relapse at 3 years was 47% (95% conﬁdence interval, 31 to 63). The 3-year progression-free (PFS) and
overall survival (OS) rates were 26% and 33%, respectively. The only signiﬁcant factor for survival was com-
plete remission versus no complete remission before transplantation (69% versus 22%, P ¼ .008); however,
complete remission was achieved only in 8 patients. Allogeneic stem cell transplantation can cure myeloﬁ-
brosis patients transformed to leukemia.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The BCR-ABLenegative myeloproliferative neoplasms of
primary myeloﬁbrosis (PMF) and the advanced forms of
essential thrombocythemia (ET) and polycythemia vera (PV;
ie, posteET/PVmyeloﬁbrosis [MF]) are chronic hematological
malignancies characterized by splenomegaly, leukoerythro-
blastosis, extramedullary hematopoiesis, and constitutive
mobilization of CD34-positive progenitor cells. Patients with
symptomatic forms of PMFhaveamedian survival of<5years
[1]. The median age at diagnosis is typically in the seventh
decade of life (median, 67 years) [2]. In about 10% to 20% ofedgments on page 281.
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13.10.027patients, PMF or posteET/PV MF transforms into acute
myeloid leukemia [3,4].
Transformed acute myeloid leukemia or blast phase in
MF is generally associated with a very poor outcome. In
one study, median survival of patients with blast phase-
myeloproliferative neoplasm BP-MPN) did not exceed
4.6  5.5 months and no signiﬁcant differences of survival
were noted between patients with PV, ET, or PMF before
transformation [5]. In another study from the Mayo Clinic,
median survival of the treated patients was 3.3 months,
whereas for those who received supportive care, median
survival was only 2.1 months [4]. Risk factors for devel-
opment of acute leukemia are advanced international
prognostic scoring systems (IPSS) [6], unfavorable cytoge-
netics [7], leukocytosis more than 30  109/L [8], or mo-
lecular abnormalities such as IDH-1/2/SRSF2, EZH2, or
ASXL1 [9].
Meanwhile, allogeneic stem cell transplantation (ASCT) is
a well-established treatment modality for PMF or posteET/
PV MF and the only potentially curative treatment [10,11].
Table 1
Patient Characteristics and Transplant Outcome
Characteristic Subgroup Number
Median age, yr (range) 55 (27-72)
Gender Male 31
Female 15
Transformed from PMF 45
Post-ET MF 1
Karyotype (n ¼ 10) Normal karyotype 2
Unfavorable karyotype 4
Other abnormalities 4
Remission induction Yes 42
No 4
Response to induction
(n ¼ 38)
CR 9
Minor or partial remission 10
19 refractory/progressive 19
Donor Matched related 17
Mismatched related 1
Matched unrelated 26
Mismatched unrelated 2
Conditioning Myeloablative 20
Reduced intensity 26
ATG use (n ¼ 44) Yes 22
No 22
Stem cell source BM 6
PBSC 38
BM þ PBSC 1
CB 1
Median follow-up, mo (range) 3.8 (0-96)
Engraftment (n ¼ 44)
Reached 39 (89%)
Not reached 8 (11%)
Acute GVHD (n ¼ 40) Overall incidence 20 (50%)
Grades II-IV 26 (18%)
Chronic GVHD (n ¼ 16) Overall incidence 6 (63%)
Extensive 4 (25%)
ATG indicates antithymocyte globulin; BM, bone marrow; PBSC, peripheral
blood stem cell; CB, cord blood; GVHD, graft-versus-host disease.
Figure 1. (A) OS and PFS after ASCT for MF transformed to acute leukemia. (B)
OS after ASCT for MF transformed to acute leukemia according to response to
induction chemotherapy.
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with advanced disease, including those with transformed
acute leukemia. Over the last few years, few studies have
been published regarding the outcome of ASCT in BP-MPN,
but the number of cases was rather small because of the
rarity of this complication. Accumulating experience is thus
widely needed to understand and optimize treatment
outcome of affected patients. This registry-based retrospec-
tive study was aimed to analyze outcome of patients with
BP-MPN and identify factors that may predict this outcome.METHODS
Cohort
A total of 1048 registry patients transplanted for MF and reported to
the European Group for Blood and Marrow Transplantation (EBMT) was
reviewed to identify 46 patients who were transplanted after acute leu-
kemia transformation. The median age of the patients was 55 years (range,
27 to 72 years) and 42 of 46 received induction chemotherapy before
transplantation from related (n ¼ 18) or unrelated (n ¼ 28) donors. Con-
ditioning regimen was either reduced intensity (n ¼ 26) or myeloablative
(n ¼ 20). Before SCT, 42 patients (91%) received induction chemotherapy.
From those patients who were assessable for response (n ¼ 38), 9 (24%)
achieved complete remission (CR), 10 (26%) achieved a minor or partial
remission, and 19 (50%) were refractory or had progressive disease at the
time of SCT. CR was deﬁned as less than 5% blasts, whereas partial
remission and minor remission were deﬁned as blast reduction of 50% and
25%, respectively. Cytogenetic data were only available in 10 patients,
showing unfavorable karyotype in 4 patients. Patient characteristics are
summarized in Table 1.Statistical Analysis
End points were OS, PFS, transplant-related mortality (TRM), and inci-
dence of relapse/progression. Characteristics of patients were expressed asmedian and range for continuous variables and frequencies for categorical
variables. Categorical data were compared with the chi-square test or
Fisher’s exact test. Survival curves were estimated by the Kaplan-Meier
method. The log-rank test was used to estimate the incidence of TRM and
relapse to account for competing risk. For treatment-related death, relapse
was the competing event, and for relapse, treatment-related death was the
competing event. The Gray test was used to compare cumulative incidence
curves. Variables tested were remission status, donor, stem cell source,
conditioning regimen, donor gender, recipient age, and acute and chronic
graft-versus-host disease.
Most calculations were performed with SPSS, version 15 (SPSS Inc,
Chicago, IL). The competing risk analyses were donewith ACCorD (V. Gebski,
NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia).RESULTS
After a median follow-up of 37.4 months (range, 1 to
109.7 months), OS and PFS at 3 years after SCT were 33% (95%
conﬁdence interval, 21 to 45) and 26% (95% conﬁdence in-
terval, 15 to 37), respectively (Figure 1A,B). In univariate
analysis, before SCT only remission status of CR versus no CR
was signiﬁcantly predictive for OS (69% versus 22%, P ¼ .008)
and PFS (55% versus 19%, P ¼ .02); however, CR was only
achieved in 8 patients. OS and PFS for patients with partial or
minor emission was 26% and 22% and did not differ from
H. Alchalby et al. / Biol Blood Marrow Transplant 20 (2014) 279e287 281those with refractory/progressive disease (22% and 19%,
P ¼ .90).
The cumulative incidence of TRM was 28% (range, 14% to
42%) at 1 year. The absence of CR before SCT was again found
to predict a signiﬁcantly increased TRM (35% versus 0%,
P¼ .053). A trend toward increased TRMwas seen in patients
transplanted from an unrelated donor compared with a
family donor (38% versus 11%, P ¼ .09).
Relapse occurred with a cumulative incidence of 47%
(range, 31% to 63%) at 3 years after ASCT. Univariate anal-
ysis could not reveal any signiﬁcant predictive factor
for relapse. Relapse rates were comparable between the
patients with CR or no CR before SCT (44% versus 46%,
P ¼ .50).
DISCUSSION
Transformation into acute leukemia occurs in about 10%
to 20% of patients with PMF or posteET/PV MF and is
associated with a poor outcome, with a median survival
<5 months [3-5]. Using reduced-intensity or myeloablative
conditioning followed by related or unrelated donor SCT,
about 25% of those patients can be cured by ASCT. The 3-
year OS and PFS is signiﬁcantly higher if patients are
transplanted after achieving CR by induction chemotherapy
before ASCT. Unfortunately, only 24% of patients who
received induction chemotherapy achieved CR, whereas 26%
achieved only minor or partial remission and 50% were
either refractory to induction chemotherapy or progressing
at time of transplantation. Interestingly, the survival beneﬁt
of patients transplanted in CR was due to a signiﬁcantly
lower TRM, whereas the cumulative incidence of relapse
was identical. No other factor, such as donor stem cell
source or intensity of the conditioning regimen, inﬂuenced
survival. There was only a trend for higher TRM after un-
related donor transplantation in comparison with HLA-
identical siblings.
However, the number of patients was rather small for
detecting signiﬁcant differences. So far, only very small series
of ASCT in transformed MF have been reported. The Mayo
Clinic reported 8 patients who received ASCT for trans-
formed MF: 5 patients were in CR at time of transplantation
and 75% were alive at 2 years after transplantation. All 5
patients with CR before transplantation were alive at 2 years
[12]. Another study from the MD Anderson Cancer Center
found that 6 of 14 patients achieved CR before trans-
plantation. Nonrelapse mortality was 29% and 2-year PFS
was 49% [13].
Previous studies have shown that postponing the trans-
plantation in MF at a more advanced stage of the disease
resulted in aworse outcome [14,15], and indeed the results of
ASCT for transformed leukemiadas reported heredare
inferior to those reported for the chronic phase of MF.
However, one third can still be cured by this approach, and
even 25% of those who were refractory or progressive to
induction chemotherapy can achieve long-term freedom
from disease. For those who achieved CR before trans-
plantation, the results are more favorable, resulting in a 3-
year PFS of 55%.We conclude that patients with MF transformed into
acute leukemia can be cured by ASCT, and achievement of CR
is the major factor for improved outcome. However, taking
into account the curative potential of ASCT and the fact that
less advanced patients may beneﬁt more from this treat-
ment, we recommend that this procedure should be
considered before MF transforms into acute leukemia.ACKNOWLEDGMENTS
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